Jam

Progyny, a leader in women’s health and family-building benefits, appointed Elizabeth Bierbower to its Board of Directors. This strategic move aims to leverage Bierbower’s three decades of healthcare experience, including leadership roles at Friday Health Plans and Humana, to support Progyny’s growth. The appointment reflects Progyny’s expansion plans and commitment to providing comprehensive solutions, focusing on improved outcomes and reduced costs.

Biohaven launched a global Phase 2/3 trial for BHV-8000, a first-in-clinic, brain-penetrant TYK2/JAK1 inhibitor, targeting neuroinflammation in Parkinson’s disease. The drug aims to address the underlying cause of disease progression, with no existing disease-modifying therapies currently available. The trial will enroll 550 patients across 13 countries to assess efficacy and safety, utilizing innovative endpoints. BHV-8000 has shown safety and tolerability, with robust brain penetration, representing a potential breakthrough in treating neurodegenerative diseases.

Ping An is showcasing its Mother’s Needlework program at London Craft Week 2025, highlighting the traditional embroidery and carpet-making skills of ethnic minority women in China. This initiative preserves cultural heritage while empowering women economically through sustainable production. The program uses recycled materials and traditional designs for eco-friendly products, promoting community development and aligning with the demand for sustainable fashion.

TotalEnergies will sell its 12.5% stake in Nigeria’s OML118 PSC to Shell for $510 million to focus on lower-emission assets. The OML118 asset includes the Bonga field, with the sale expected to reduce TotalEnergies’ Nigerian output by approximately 11,000 barrels of oil equivalent per day in 2024. This move aligns with TotalEnergies’ strategy to streamline its portfolio and concentrate on existing gas and offshore oil projects, including the Ubeta project.

Faraday Future announced the results of its Annual General Meeting, with shareholders approving key proposals including production of FX vehicles by late 2025. The company received shareholder support for financial health initiatives and strategic plans, including the FX Super One launch. The meeting also included the re-election of the board of directors and approval of share authorization. FF is aiming to have the first FX vehicle on the production line by the close of 2025.

Taysha Gene Therapies (TSHA) announced a public offering to raise approximately $200 million. The offering includes common stock and pre-funded warrants, priced at $2.75 and $2.749 per share respectively. This capital will advance Taysha’s CNS-focused gene therapy programs, targeting diseases like Rett syndrome with its AAV-based therapies. The deal is expected to close around May 30, 2025.

Rumble, the video platform, supports President Trump and Secretary Rubio’s efforts to restrict visas for those censoring Americans, aligning with its commitment to free speech. This follows Rumble’s lawsuit against a Brazilian Supreme Court Justice, alleging censorship of a US user’s account violating First Amendment rights. The company views the US stance as crucial in defending digital sovereignty and free expression against global overreach.

BioSig Technologies and Streamex Exchange have appointed Mitch Williams, CFA, as Chief Investment Officer, a move aimed at tokenizing real-world assets, particularly commodities. Williams brings over two decades of capital markets experience, including leadership roles at OppenheimerFunds and Wafra Inc. His expertise will guide Streamex’s commodity market strategy, leveraging blockchain technology to unlock value in the $142.85 trillion global commodity market.

Johnson & Johnson will release its second-quarter results on Wednesday, July 16th, at 8:30 AM Eastern Time. Led by CEO Joaquin Duato, the call will cover the company’s performance and strategy. Investors can access the webcast and presentation materials on J&J’s website, as well as dial-in for the call. Replays will also be available. The press release will be available that morning. The tentative date for the Q3 earnings call is October 14, 2025.

Chesapeake Bank has appointed Grant Garber as Assistant VP, Director of Fraud Prevention, and Nate Cobb as Assistant VP, Director of Operations. Garber will lead the new fraud prevention department, leveraging his compliance expertise. Cobb, with his operational background, will oversee operational infrastructure. These appointments, following the bank’s AARP BankSafe Trained Seal award, reflect Chesapeake Bank’s commitment to strengthening security, optimizing operations, and enhancing customer experience.